12:00 AM
Feb 22, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Ampligen: Began Phase II/III trials

Hemispherx Biopharma Inc. (HEB), Philadelphia, Penn.
Product: Ampligen
Business: Infectious diseases
Therapeutic category: Viral replication

Read the full 67 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >